Abstract | BACKGROUND: METHODS: Rats were treated with TAC (1.5 mg/kg, subcutaneously) and the DPP IV inhibitor MK-0626 (10 or 20 mg/kg, oral gavage) for 4 weeks. The effect of MK-0626 on TAC-induced diabetes was evaluated by assessing pancreatic islet function, histopathology. TAC-induced incretin dysfunction was also examined based on active glucagon-like peptide-1 (GLP-1) levels in the serum after glucose loading. The protective effect of MK-0626 was evaluated by measuring markers of oxidative stress, oxidative resistance, and apoptosis. To determine whether enhanced GLP-1 signaling is associated with these protective effects, we measured the expression of the GLP-1 receptor (GLP-1R) and the effect of the GLP-1 analog exendin-4 on cell viability and oxidative stress in isolated islets. RESULTS: CONCLUSIONS:
|
Authors | Long Jin, Sun Woo Lim, Kyoung Chan Doh, Shang Guo Piao, Jian Jin, Seong Beom Heo, Byung Ha Chung, Chul Woo Yang |
Journal | PloS one
(PLoS One)
Vol. 9
Issue 6
Pg. e100798
( 2014)
ISSN: 1932-6203 [Electronic] United States |
PMID | 24959755
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Dipeptidyl-Peptidase IV Inhibitors
- Protective Agents
- 8-Hydroxy-2'-Deoxyguanosine
- Deoxyguanosine
- Tacrolimus
|
Topics |
- 8-Hydroxy-2'-Deoxyguanosine
- Animals
- DNA Damage
(drug effects)
- Deoxyguanosine
(analogs & derivatives, blood, urine)
- Diabetes Mellitus, Experimental
- Dipeptidyl-Peptidase IV Inhibitors
(pharmacology)
- Islets of Langerhans
(drug effects, pathology)
- Male
- Protective Agents
(pharmacology)
- Rats
- Rats, Sprague-Dawley
- Tacrolimus
(adverse effects)
|